In this study, we tested if TMAO can boost the tendency to SLE development and T cell activation and proliferation in secondary lymph organs, causing endothelial dysfunction and hypertension in a lupus model induced by epicutaneous application of the TLR7 agonist imiquimod (IMQ). Here, TLR7 is linked to systemic lupus erythematosus.